Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

Inclusion Criteria

• •1. Subjects met the criteria for recurrence after allogeneic transplantation: re-emergence of leukemia cells or bone marrow original cells in peripheral blood \>5% (except for other causes such as bone marrow recovery period) or extramedullary leukemia cell infiltration or molecular or cytogenetic recurrence.
• •2. Bone marrow molecular biology detected C-KIT D816 or C-KIT N822 mutations
• •3. Patients with CBFB::MYH11 gene or RUNX1::RUNX1T1 fusion gene detected.
• •4. Eastern Cancer Collaboration Group (ECOG) physical status score 0-2 points.
• •5. Liver, kidney and cardiopulmonary functions met the following requirements: Within 2 weeks before enrollment ① creatinine ≤1.5 upper limit of normal value; ② Left ventricular ejection fraction ≥50%; ③ Blood oxygen saturation \>91%; ④ Total bilirubin ≤2×ULN; ALT and AST≤2.5 x ULN; Myocardial enzymes \< 2 times the upper limit of normal (for the same age)
• •6. Volunteer to participate in clinical studies and sign informed consent, willing to follow and able to complete all trial procedures.